Harken Health charges customers nothing out of pocket for primary care visits to the insurer's clinics, but it bled cash. » Read More
Despite a recently lifted travel advisory, there are signs of pain in Florida's $90 billion travel industry.
Regulators said they have told Mylan that it should be paying higher rebates on sales of EpiPens through Medicaid.
Young adults continue to have high rates of uninsurance despite gains made under Obamacare.
A restatement by Mylan of EpiPen profit figures is just the latest problem for the drugmaker.
Mylan said on Monday the auto-injector EpiPen pretax profits were higher than it told Congress, according to Dow Jones.
A potent opioid called carfentanil has led to hundreds of overdoses in Ohio, overwhelming police and first responders, NPR reports.
The cost of naloxone has spiraled upwards, even as the drug has become more desperately needed to reverse overdoses.
Shares of Endo International surged as much as 18 percent after the company named a new CEO and projected upbeat full-year earnings.
The nation's uninsured rate would spike under Trump's health plan, but fall further under Clinton's, a study finds.
The optics of Mylan CEO Heather Bresch's use of a private jet to fly to her testimony before Congress may not have been ideal.
Mylan also faces heat from multiple regulatory and legal agencies over huge cost increases for the anti-allergy auto-injectors.
A drugmaker producing acne creams has raised the price of two of its treatments to almost $10K a tube, the Financial Times reports.
Mylan CEO Heather Bresch is set to testify Wednesday before a House committee over sky-high price hikes for lifesaving EpiPens.
Less than 10 percent of authorized doctors prescribe the medication buprenorphine to more than 75 patients.
Shares of Sarepta Therapeutics jumped more than 13 percent in Tuesday trade after closing higher Monday on government approval of its drug.
GlaxoSmithKline said it had chosen its head of consumer health care, Emma Walmsley, as its new CEO, after considering other candidates.
Get the best of CNBC in your inbox